{"id":"rituximab-and-everolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Renal dysfunction"},{"rate":null,"effect":"Mouth ulcers"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab is a chimeric monoclonal antibody that binds CD20 on B cell surfaces, leading to B cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Everolimus is an mTOR inhibitor that suppresses T cell and B cell proliferation and activation. The combination targets both adaptive immune cell populations to reduce autoimmune and alloimmune responses.","oneSentence":"This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:12.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Antibody-mediated rejection in kidney transplant recipients"},{"name":"Autoimmune conditions with B cell involvement"}]},"trialDetails":[{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT01665768","phase":"PHASE2","title":"Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-09","conditions":"CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)","enrollment":56},{"nctId":"NCT01125293","phase":"PHASE1, PHASE2","title":"Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2010-04","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01334502","phase":"PHASE1","title":"Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-03","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT01567475","phase":"PHASE1","title":"The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2011-12","conditions":"Non-Hodgkin's Lymphomas","enrollment":21},{"nctId":"NCT00869999","phase":"PHASE2","title":"Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":26},{"nctId":"NCT01312064","phase":"PHASE4","title":"De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2011-04","conditions":"Renal Insufficiency","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mabthera"],"phase":"marketed","status":"active","brandName":"rituximab and everolimus","genericName":"rituximab and everolimus","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation. Used for Antibody-mediated rejection in kidney transplant recipients, Autoimmune conditions with B cell involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}